company background image
DPM logo

Sumitomo Pharma DB:DPM Stock Report

Last Price

€2.40

Market Cap

€977.3m

7D

0.8%

1Y

-57.1%

Updated

27 Mar, 2024

Data

Company Financials +

Sumitomo Pharma Co., Ltd.

DB:DPM Stock Report

Market Cap: €977.3m

DPM Stock Overview

Sumitomo Pharma Co., Ltd. engages in the manufacture and sale of pharmaceuticals, food ingredients and additives, veterinary medicines, and others in Japan, North America, China, and internationally.

DPM fundamental analysis
Snowflake Score
Valuation3/6
Future Growth1/6
Past Performance0/6
Financial Health0/6
Dividends0/6

Sumitomo Pharma Co., Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Sumitomo Pharma
Historical stock prices
Current Share PriceJP¥2.40
52 Week HighJP¥5.90
52 Week LowJP¥2.04
Beta0.57
1 Month Change13.21%
3 Month Change-18.92%
1 Year Change-57.14%
3 Year Change-83.45%
5 Year Change-88.45%
Change since IPO-74.74%

Recent News & Updates

Recent updates

Shareholder Returns

DPMDE PharmaceuticalsDE Market
7D0.8%2.3%1.9%
1Y-57.1%-25.9%7.3%

Return vs Industry: DPM underperformed the German Pharmaceuticals industry which returned -25.9% over the past year.

Return vs Market: DPM underperformed the German Market which returned 7.3% over the past year.

Price Volatility

Is DPM's price volatile compared to industry and market?
DPM volatility
DPM Average Weekly Movement7.4%
Pharmaceuticals Industry Average Movement6.3%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.1%
10% least volatile stocks in DE Market2.4%

Stable Share Price: DPM's share price has been volatile over the past 3 months.

Volatility Over Time: DPM's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
18976,250Hiroshi Nomurahttps://www.sumitomo-pharma.com

Sumitomo Pharma Co., Ltd. engages in the manufacture and sale of pharmaceuticals, food ingredients and additives, veterinary medicines, and others in Japan, North America, China, and internationally. The company offers pharmaceutical products, such as therapeutic agents for Parkinson’s disease, uterine fibroids, depression, type 2 diabetes, systemic fungal infection, hypertension, pruritus, advanced prostate cancer, overactive bladder, chronic obstructive pulmonary disease, angina pectoris, and arrhythmia. It provides products for atypical antipsychotic, cultured thymus tissue for pediatric congenital athymia, antiepileptic, and carbapenem antibiotic; and Fabry disease drugs.

Sumitomo Pharma Co., Ltd. Fundamentals Summary

How do Sumitomo Pharma's earnings and revenue compare to its market cap?
DPM fundamental statistics
Market cap€977.32m
Earnings (TTM)-€1.06b
Revenue (TTM)€2.02b

0.5x

P/S Ratio

-0.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
DPM income statement (TTM)
RevenueJP¥330.31b
Cost of RevenueJP¥132.34b
Gross ProfitJP¥197.96b
Other ExpensesJP¥371.68b
Earnings-JP¥173.72b

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

May 14, 2024

Earnings per share (EPS)-437.26
Gross Margin59.93%
Net Profit Margin-52.59%
Debt/Equity Ratio119.9%

How did DPM perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.